[go: up one dir, main page]

WO1998006425A1 - Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine - Google Patents

Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine Download PDF

Info

Publication number
WO1998006425A1
WO1998006425A1 PCT/SE1997/001344 SE9701344W WO9806425A1 WO 1998006425 A1 WO1998006425 A1 WO 1998006425A1 SE 9701344 W SE9701344 W SE 9701344W WO 9806425 A1 WO9806425 A1 WO 9806425A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactoferrin
lactoferricin
treatment
pharmaceutical composition
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1997/001344
Other languages
English (en)
Inventor
Lars Å HANSON
Inger Mattsby-Baltzer
Cecilia Motas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A+ Science AB
Original Assignee
A+ Science Invest AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+ Science Invest AB filed Critical A+ Science Invest AB
Priority to EP97935939A priority Critical patent/EP0920331A1/fr
Priority to AU38727/97A priority patent/AU3872797A/en
Priority to JP50964098A priority patent/JP2001504447A/ja
Priority to CA002263416A priority patent/CA2263416A1/fr
Publication of WO1998006425A1 publication Critical patent/WO1998006425A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the iron-binding lactoferrin is also present in specific granules of polymorphonuclear leucocytes and in other exocrine secretions than milk such as saliva, tears and bronchial mucus, as well as cervical secretion, amni- otic fluid, decidua, and trophoblasts (see e.g. Montreuil J., et al., Isolement d'une lactosiderophiline du lait de appropriate, CR Acad. Sci. Paris 250 D: 1736-37, 1960; Montreuil J., et al., Preparation et proprietes de la lactosiderophiline (lactotransferrine) du fait de an, Biochim. Biophys.
  • IL-6 response when added to fresh monocytes or cultured monocytic cells.
  • Prevention refers to minimizing, reducing or sup- pressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.
  • a “patient” is a subject at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition.
  • An “effective amount” is an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious condition.
  • the pharmaceutical composi- tion according to the present invention is formulated for oral administration.
  • lactoferrin and lactoferricin used according to the present invention can e.g. be obtained through isola- tion and purification from natural sources, such as human milk, through use of genetic engineering techniques, such as recombinant expression or direct production in genetically altered animals, or through chemical synthesis.
  • the lactoferricin can also be obtained by enzymatic degrada- tion of lactoferrin (hydrolysate) .
  • the lactoferrin used according to the present invention is preferably human lactoferrin or bovine lactoferrin, and it is preferably administered as a hydrolysate.
  • the lactoferricin used according to the present in- vention is preferably human lactoferricin or bovine lactoferricin.
  • the pharmaceutical composition comprising lactoferrin and/or lactoferricin according to the present invention is particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by the fungus Candida albicans.
  • the pharmaceutical composition according to the present invention is also well suited for preventive medical care by reducing the risk of developing urinary tract in- fection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications .
  • lactoferrin and/or lactoferricin in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants.
  • Fig. 1 a - d illustrate bacterial recovery from the kidney (a and b) and bladder (c and d) , respectively, of C3H/Tif and C3H/HeN mice infected with E. coli in the urinary tract and perorally given human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
  • LF hum human lactoferrin
  • LF bov bovine lactoferrin
  • Fig. 5 illustrates the cytokine concentration in serum from mice with experimentally induced colitis after treatment with bovine lactoferrin (LF bov) compared to a control group not receiving lac- toferrin.
  • LF bov bovine lactoferrin
  • lactoferrin The antibacterial and anti-inflammatory properties of lactoferrin were explored by studying the effects of lactoferrin given to mice (C3H/Tif and C3H/HeN) with experimentally induced urinary tract infection (UTI) .
  • Urine samples from the mice were collected 0, 2, 5, and 24 hours after infection. 50 ⁇ l of each of the undiluted urine samples were cultured. The number of leucocytes in uncentrifuged urine was analyzed for each sample. The remaining urine from each animal at each sampling time was centrifuged and saved for IL-6 analysis. After 24 h the mice were bled and killed. The bladder and kidneys were taken out aseptically. The organs were homogenized, and serial dilutions thereof (bladder 1/1, 1/10, kidneys 1/1, 1/10, 1/100, 1/1000) were cultured on Drigalsky plates.
  • a significant p value should be adjusted to p ⁇ 0.025 t illustrates a significant increase in the treatment group compared to the infected but untreated control group.
  • I illustrates a significant decrease in the treatment group compared to the infected but untreated control group.
  • lactoferrin both human and bovine significantly decreased the number of bacteria in the urinary tract of the infected mice, compared to the control group.
  • Acute colitis was induced in C57BI/6J mice by giving 5% dextransulphate in the drinking water for 6 days.
  • Human lactoferrin was orally given to ten mice twice a day in a dose of 1 mg/mouse, starting from day 3 of the experiment.
  • Two control groups (in total 17 mice) were given the same volume of drinking water or bovine serum albumin (BSA) (2 mg per mouse and day) .
  • BSA bovine serum albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Polymers & Plastics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comprenant de la lactoferrine et/ou de la lactoferricine et destinée au traitement et/ou à la prévention d'infections, d'inflammations et/ou de tumeurs. L'invention se rapporte également à l'utilisation de lactoferrine et de lactoferricine dans la production d'une composition pharmaceutique destinée au traitement et/ou à la prévention d'infections, d'inflammations et de tumeurs, ainsi qu'à un procédé de traitement et/ou de prévention d'infections, d'inflammations et/ou de tumeurs, ce procédé consistant à administrer de la lactoferrine et/ou de la lactoferricine. L'invention est notamment conçue pour le traitement et/ou la prévention d'infections de l'appareil urinaire et les colites. De préférence, on administre oralement la lactoferrine et/ou lactoferricine de l'invention. En outre, on peut inclure dans un aliment pour nourrissons la composition comprenant la lactoferrine et/ou lactoferricine.
PCT/SE1997/001344 1996-08-12 1997-08-12 Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine Ceased WO1998006425A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97935939A EP0920331A1 (fr) 1996-08-12 1997-08-12 Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine
AU38727/97A AU3872797A (en) 1996-08-12 1997-08-12 Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
JP50964098A JP2001504447A (ja) 1996-08-12 1997-08-12 ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防
CA002263416A CA2263416A1 (fr) 1996-08-12 1997-08-12 Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2376196P 1996-08-12 1996-08-12
US60/023,761 1996-08-12

Publications (1)

Publication Number Publication Date
WO1998006425A1 true WO1998006425A1 (fr) 1998-02-19

Family

ID=21817049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1997/001344 Ceased WO1998006425A1 (fr) 1996-08-12 1997-08-12 Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine

Country Status (5)

Country Link
EP (1) EP0920331A1 (fr)
JP (1) JP2001504447A (fr)
AU (1) AU3872797A (fr)
CA (1) CA2263416A1 (fr)
WO (1) WO1998006425A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001730A1 (fr) * 1998-07-06 2000-01-13 A+ Science Invest Ab Peptides reposant sur la sequence de la lactoferrine humaine et leur utilisation
WO2000012541A3 (fr) * 1998-08-28 2000-06-08 Alpharma As Peptides bioactifs
JP2002241301A (ja) * 2001-02-15 2002-08-28 Meiji Milk Prod Co Ltd 炎症に伴う症状の軽減剤
WO2001019852A3 (fr) * 1999-08-31 2002-09-12 Alpharma As Preparation de peptides
EP0980261A4 (fr) * 1997-05-03 2003-04-23 Univ Texas Methodes de prevention et de traitement du desequilibre metabolique induit par insulte chez les humains et des animaux
WO2003082921A1 (fr) * 2002-04-03 2003-10-09 Fonterra Research Centre Limited Lactoferrine
WO2003088914A3 (fr) * 2002-04-18 2004-02-26 Univ Iowa Res Found Procede pour inhiber et traiter de films biologiques au moyen de chelateurs metalliques
GB2396810A (en) * 2002-12-20 2004-07-07 Richard John Cleeve Bird Feed
WO2006001766A1 (fr) * 2004-06-23 2006-01-05 Nestor Medical Ab Composition comprenant de l'acide lactique et de la lactoferrine
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
WO2009050279A1 (fr) 2007-10-19 2009-04-23 Pharmasurgics In Sweden Ab Nouveaux peptides synthétiques et leur utilisation
US7901879B2 (en) 2002-05-10 2011-03-08 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2012094098A1 (fr) * 2011-01-05 2012-07-12 Mead Johnson Nutrition Company Composition contenant des protéines de lait thermolabiles et procédé de préparation associé
EP2481751A1 (fr) 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Homme peptides dérivés de lactoferrine
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
WO2014097123A1 (fr) 2012-12-17 2014-06-26 Progine Farmaceutici S.R.L. Composition pour application topique comprenant de la lactoferrine
US8815812B2 (en) 2007-11-14 2014-08-26 Inger Mattsby-Baltzer Synthetic arginine substituted peptides and their use
EP2992894A1 (fr) 2014-09-05 2016-03-09 Progine Farmaceutici Srl Formulations vaginales pour prévenir et traiter des infections vaginale et cervico-vaginale
WO2021222584A3 (fr) * 2020-04-29 2021-12-02 The Regents Of The University Of Michigan Inhibition d'entrée virale du sras-cov-2 par administration de lactoferrine et ses utilisations
CN116036054A (zh) * 2023-03-07 2023-05-02 广州见华医学科技有限公司 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途
CN116327740A (zh) * 2023-03-07 2023-06-27 广州见华医学科技有限公司 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途
EP4523699A1 (fr) * 2023-09-15 2025-03-19 FB Dermo srl Composition dermatologique anti-inflammatoire comprenant du glycerophosphoinositol, un hydrolysat de lactoferrine et un cannabinoïde, notamment pour le traitement de la dermatite séborrhéique
US12447200B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5872131B2 (ja) * 2006-11-29 2016-03-01 ロート製薬株式会社 抗真菌医薬組成物
JP2011051914A (ja) * 2009-08-31 2011-03-17 Obihiro Univ Of Agriculture & Veterinary Medicine 低温殺菌処理ホエータンパク濃縮物を含む腸管炎症抑制剤
JP5177901B2 (ja) * 2009-12-02 2013-04-10 株式会社明治 栄養組成物
JP5763024B2 (ja) * 2012-09-07 2015-08-12 株式会社明治 栄養組成物
CN106794218A (zh) * 2014-10-08 2017-05-31 学校法人庆应义塾 白细胞的细胞外诱捕网形成抑制剂

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506651A2 (fr) * 1991-03-25 1992-09-30 IMMUNO Aktiengesellschaft Préparations pharmaceutiques sur la base de protéines plasmatiques
EP0568200A2 (fr) * 1992-04-02 1993-11-03 Immuno Japan Inc. Compositions pharmaceutiques et alimentaires contenant des transferrines et des agents antibactériens pour améliorer l'activité des dépenses immunitaires et pour le traitement d'infections
EP0629347A1 (fr) * 1992-01-23 1994-12-21 Morinaga Milk Industry Co., Ltd. Agent antibacterien et traitement d'articles au moyen de cet agent
EP0730868A1 (fr) * 1995-02-17 1996-09-11 Tamotsu Satoh Médicaments formulés pour le traitement d'inflammations orales et produits alimentaires préparés pour le traitment et la prévention de la stomatite
EP0753308A2 (fr) * 1995-07-12 1997-01-15 Gambit International Limited Utilisation de lactoferrine pour la thérapie de maladies infectieuses aigues ou récurrentes causées par Streptococcus pyogenes ou d'autres bactéries pathogènes gram-positives intracellulaires
WO1997005884A1 (fr) * 1995-08-07 1997-02-20 New England Medical Center Hospitals, Inc. Aliment lacte pour nourrissons et additifs correspondants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506651A2 (fr) * 1991-03-25 1992-09-30 IMMUNO Aktiengesellschaft Préparations pharmaceutiques sur la base de protéines plasmatiques
EP0629347A1 (fr) * 1992-01-23 1994-12-21 Morinaga Milk Industry Co., Ltd. Agent antibacterien et traitement d'articles au moyen de cet agent
EP0568200A2 (fr) * 1992-04-02 1993-11-03 Immuno Japan Inc. Compositions pharmaceutiques et alimentaires contenant des transferrines et des agents antibactériens pour améliorer l'activité des dépenses immunitaires et pour le traitement d'infections
EP0730868A1 (fr) * 1995-02-17 1996-09-11 Tamotsu Satoh Médicaments formulés pour le traitement d'inflammations orales et produits alimentaires préparés pour le traitment et la prévention de la stomatite
EP0753308A2 (fr) * 1995-07-12 1997-01-15 Gambit International Limited Utilisation de lactoferrine pour la thérapie de maladies infectieuses aigues ou récurrentes causées par Streptococcus pyogenes ou d'autres bactéries pathogènes gram-positives intracellulaires
WO1997005884A1 (fr) * 1995-08-07 1997-02-20 New England Medical Center Hospitals, Inc. Aliment lacte pour nourrissons et additifs correspondants

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 124, No. 24, 10 June 1996, (Columbus, Ohio, USA), page 1, Abstract No. 325373; & JP,A,08 059 500, (SHIMAMURA SEIICHI et al.), (05-03-96). *
DIALOG INFORMATION SERVICE, File 155, Medline, Dialog Accession No. 07325914, Medline Accession No. 93146928, BELLAMY W. et al., "Antibacterial Spectrum of Lactoferricin B, a Potent Bactericidal Peptide Derived from the N-Terminal Region of Bovine Lactoferrin"; & J. APPL. BACTERIOL. (ENGLAND), Dec. 1992, 73(6), p *
FILE WPI, Derwent Accession No. 96-350155, KURIIWA N., "Drug for Inhibition of Endotoxin-Induced Inflammation Comprises Peptide of Mol. Wt. 10000, Derived from N-Terminal Region of Comprises Peptide of Mol. Wt. 1000, Derived from N-Terminal Region of Lactoferrin"; & JP,A,08 165 248, (25-06-96), DW9635. *
PATENT ABSTRACTS OF JAPAN, Vol. 88, No. 27; & JP,A,63 051 337 (SNOW BRAND MILK PROD CO LTD), 4 March 1988. *
PATENT ABSTRACTS OF JAPAN, Vol. 96, No. 29; & JP,A,07 309 771 (MORINAGA MILK IND CO LTD), 28 November 1995. *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0980261A4 (fr) * 1997-05-03 2003-04-23 Univ Texas Methodes de prevention et de traitement du desequilibre metabolique induit par insulte chez les humains et des animaux
WO2000001730A1 (fr) * 1998-07-06 2000-01-13 A+ Science Invest Ab Peptides reposant sur la sequence de la lactoferrine humaine et leur utilisation
US7803757B2 (en) 1998-07-06 2010-09-28 Pharmasurgics In Sweden Ab Peptides based on the sequence of human lactoferrin and their use
JP2010090162A (ja) * 1998-07-06 2010-04-22 Pharmasurgics In Sweden Ab 人ラクトフェリンの配列に基づくペプチドおよびその使用
US7253143B1 (en) 1998-07-06 2007-08-07 Pharmasurgics In Sweden Ab Peptides based on the sequence of human lactoferrin and their use
US9109048B2 (en) 1998-08-21 2015-08-18 Lytix Biopharma As Inhibition of tumor growth
WO2000012541A3 (fr) * 1998-08-28 2000-06-08 Alpharma As Peptides bioactifs
US6890902B2 (en) 1998-08-28 2005-05-10 Alpharma As Cytotoxic modified lactoferrin peptides
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
US8143211B2 (en) 1998-08-28 2012-03-27 Lytix Biopharma As Bioactive peptides
US7439228B2 (en) 1998-08-28 2008-10-21 Lytix Biopharma As Bioactive peptides
WO2000012542A3 (fr) * 1998-08-28 2000-06-29 Alpharma As Peptides bioactifs
WO2001019852A3 (fr) * 1999-08-31 2002-09-12 Alpharma As Preparation de peptides
US7393824B1 (en) 2000-03-09 2008-07-01 Lytix Biopharma Methods of peptide preparation
JP2002241301A (ja) * 2001-02-15 2002-08-28 Meiji Milk Prod Co Ltd 炎症に伴う症状の軽減剤
US8703699B2 (en) 2002-04-03 2014-04-22 Auckland Uniservices Limited Lactoferrin
WO2003082921A1 (fr) * 2002-04-03 2003-10-09 Fonterra Research Centre Limited Lactoferrine
US7446089B2 (en) 2002-04-18 2008-11-04 Singh Pradeep K Methods of inhibiting and treating bacterial biofilms by metal chelators
WO2003088914A3 (fr) * 2002-04-18 2004-02-26 Univ Iowa Res Found Procede pour inhiber et traiter de films biologiques au moyen de chelateurs metalliques
US8343911B2 (en) 2002-04-18 2013-01-01 University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators
US7901879B2 (en) 2002-05-10 2011-03-08 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US8242079B2 (en) 2002-05-10 2012-08-14 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
GB2396810A (en) * 2002-12-20 2004-07-07 Richard John Cleeve Bird Feed
US8105615B2 (en) 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
RU2398575C2 (ru) * 2004-06-23 2010-09-10 Нестор Медикал Аб Композиция, содержащая молочную кислоту и лактоферрин
WO2006001766A1 (fr) * 2004-06-23 2006-01-05 Nestor Medical Ab Composition comprenant de l'acide lactique et de la lactoferrine
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
US7420033B2 (en) 2004-10-26 2008-09-02 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
WO2009050279A1 (fr) 2007-10-19 2009-04-23 Pharmasurgics In Sweden Ab Nouveaux peptides synthétiques et leur utilisation
US8815812B2 (en) 2007-11-14 2014-08-26 Inger Mattsby-Baltzer Synthetic arginine substituted peptides and their use
WO2012094098A1 (fr) * 2011-01-05 2012-07-12 Mead Johnson Nutrition Company Composition contenant des protéines de lait thermolabiles et procédé de préparation associé
CN103338657A (zh) * 2011-01-05 2013-10-02 Mjn美国控股有限责任公司 包含热不稳定乳蛋白的组合物及其制备方法
EP2661180B1 (fr) 2011-01-05 2016-09-28 MJN U.S. Holdings LLC Composition contenant des protéines de lait thermolabiles et procédé de préparation associé
US9132165B2 (en) 2011-01-26 2015-09-15 Pergamum Ab Synthetic peptides and their use
US8846608B2 (en) 2011-01-26 2014-09-30 Pergamum Ab Human lactoferrin derived peptides and their use
EP2481751A1 (fr) 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Homme peptides dérivés de lactoferrine
WO2012101156A2 (fr) 2011-01-26 2012-08-02 Pharmasurgics In Sweden Ab Nouveaux peptides synthétiques et leur utilisation
WO2012101157A1 (fr) 2011-01-26 2012-08-02 Pharmasurgics In Sweden Ab Peptides dérivés de la lactoferrine humaine et leur utilisation
WO2014097123A1 (fr) 2012-12-17 2014-06-26 Progine Farmaceutici S.R.L. Composition pour application topique comprenant de la lactoferrine
EP2992894A1 (fr) 2014-09-05 2016-03-09 Progine Farmaceutici Srl Formulations vaginales pour prévenir et traiter des infections vaginale et cervico-vaginale
US12447200B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
WO2021222584A3 (fr) * 2020-04-29 2021-12-02 The Regents Of The University Of Michigan Inhibition d'entrée virale du sras-cov-2 par administration de lactoferrine et ses utilisations
CN116036054B (zh) * 2023-03-07 2024-04-26 湖北嫦娥生物股份有限公司 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途
CN116327740B (zh) * 2023-03-07 2024-07-02 苏州青珩信息科技有限公司 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途
CN116327740A (zh) * 2023-03-07 2023-06-27 广州见华医学科技有限公司 一种乳铁蛋白贴剂及其在制备用于儿童反复呼吸道感染治疗药物中的用途
CN116036054A (zh) * 2023-03-07 2023-05-02 广州见华医学科技有限公司 一种乳铁蛋白贴剂及其在制备用于肿瘤患者术后康复治疗药物中的用途
EP4523699A1 (fr) * 2023-09-15 2025-03-19 FB Dermo srl Composition dermatologique anti-inflammatoire comprenant du glycerophosphoinositol, un hydrolysat de lactoferrine et un cannabinoïde, notamment pour le traitement de la dermatite séborrhéique

Also Published As

Publication number Publication date
CA2263416A1 (fr) 1998-02-19
EP0920331A1 (fr) 1999-06-09
AU3872797A (en) 1998-03-06
JP2001504447A (ja) 2001-04-03

Similar Documents

Publication Publication Date Title
EP0920331A1 (fr) Traitement et prevention d'infections, d'inflammations et/ou de tumeurs a l'aide de lactoferrine et/ou de lactoferricine
Togawa et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance
Egea et al. GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa
Inoue et al. Composition and physiological functions of the porcine colostrum
Broide et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
Finotto et al. Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo
Iigo et al. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine
Conti et al. Cultures of astrocytes and microglia express interleukin 18
Ginkel et al. Partial IgA-deficiency with increased Th2-type cytokines in TGF-β1 knockout mice
Ogawa et al. Regulated production of the chemokine CCL28 in human colon epithelium
Fu et al. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF.
KR100297959B1 (ko) 유장단백질로hiv-혈청양성개체의치료방법
IL129211A (en) Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders
Crocker et al. Regulation of a murine macrophage haemagglutinin (sheep erythrocyte receptor) by a species-restricted serum factor
Bodammer et al. Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin
JP4668534B2 (ja) 免疫反応を調節するためのエナメルマトリックスタンパク質組成物
Yanagi et al. In VivoRole of IL-10 and IL-12 during Development of Sjögren's Syndrome in MRL/lprMice
JPH06503320A (ja) 再活性化酸素種に対する防御剤の使用
Faust et al. In vitro Modulation of C1q mRNA Expression and Secretion by Interleukin-1, Interleukin-6, and Interferon-g in Resident and Stimulated Murine Peritoneal Macrophages
US7592310B2 (en) Induction of antibiotic proteins and peptides by LAIT/sCD14-protein
US6613741B2 (en) Method for treating aseptic SIRS in humans and other animals
US7115568B2 (en) Methods using TCF II
Toft et al. Effect of hemodiafiltration and sepsis on chemotaxis of granulocytes and the release of IL‐8 and IL‐10
JP4787445B2 (ja) 抗原特異的ＩｇＥ抗体産生抑制剤
US5998370A (en) Agents for the prevention and/or treatment of radiation-induced disorders by administrating TCF-II

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE ES FI FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997935939

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 509640

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 509640

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2263416

Country of ref document: CA

Ref country code: CA

Ref document number: 2263416

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09248287

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997935939

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997935939

Country of ref document: EP